Register Now for OpticalCEUs Spring 2015 Continuing Education Conference!!

Seats are vanishing quickly for OpticalCEUs Spring 2015 Continuing Education Seminar for Opticians.
So if you need to earn ABO and NCLE
continuing education credits,
sign up NOW for OpticalCEUs Spring 2015 conference.

Tuesday, January 22, 2013

Protocols for AMD Trials Amended

Advanced Cell Technology, Inc. (ACT), is amending the patient treatment protocol for the remainder of it Phase I clinical trials for Stargardt’s macular dystrophy (SMD) and dry age-related macular degeneration (dry AMD) currently being conducted in the U.S. and will also submit an amendment in Europe for the SMD trial being conducted there, announced a company spokesperson. Patients with better vision, better than 20/100, will be eligible for enrollment in the remainder of the trials. By treating patients earlier in the course of the disease, ACT believes that the amended patient protocol will have a more significant impact on photoreceptor rescue and visual function. In previous protocols, only SMD patients with a visual acuity no better than hand movement in the treated eyes and dry AMD patients with a visual acuity of 20/400 were eligible. Read more.

No comments:

Post a Comment

Post a Comment